Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 20/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.51 |
| ▸ | CDC42BPG | Q6DT37 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16129148 | 0.93 | BUB1 (0.71) | BUB1SLC28A1STK10HTR1ADDR1 | |
| SCHEMBL16129141 | 0.85 | BUB1 (0.64) | BUB1SLC28A1STK10HTR1ADDR1 | |
| SCHEMBL16097898 | 0.85 | BUB1 (0.76) | BUB1 | |
| SCHEMBL16129160 | 0.84 | BUB1 (0.75) | BUB1 | |
| SCHEMBL16129187 | 0.84 | BUB1 (0.62) | BUB1SLC28A1STK10HTR1ADDR1 | |
| SCHEMBL16129094 | 0.78 | BUB1 (0.70) | BUB1 | |
| SCHEMBL16098136 | 0.78 | BUB1 (0.73) | BUB1SLC28A1STK10HTR1ADDR1 | |
| SCHEMBL19381217 | 0.77 | BUB1 (0.79) | BUB1 | |
| SCHEMBL14843099 | 0.76 | BUB1 (1.00) | BUB1 | |
| SCHEMBL16129110 | 0.76 | BUB1 (0.78) | BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | claimed |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | US | claimed |
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | US | disclosed |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | US | disclosed |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-18 | — | — | US | disclosed |
| WO-2014147204-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275268-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | BUB1 1/4885SLC28A1 3923/4885STK10 239/4885 |
| US-20160046604-A1 | HETEROARYL SUBSTITUTED INDAZOLES | BUB1, BUB1B, BUB3 | BUB1 1/4885SLC28A1 3942/4885STK10 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.